A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -1.61% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 84.85%. Over the past 30 days, the price of CRDF has fallen by 6.48%. And in the last five days, it has fallen by -4.26%.
The market performance of Cardiff Oncology Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $6.42 on 03/25/24, with the lowest value for the same timeframe being $2.01, recorded on 08/05/24.
52-week price history of CRDF Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Cardiff Oncology Inc’s current trading price is -33.49% away from its 52-week high, while its distance from the 52-week low is 112.44%. The stock’s price range for this period has been between $2.01 and $6.42. The Healthcare sector company’s shares saw a trading volume of about 1.28 million for the day, which was lower than the average daily volume of 2.24 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Cardiff Oncology Inc (CRDF) has experienced a quarterly rise of 63.60% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 284.06M and boasts a workforce of 33 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.54, with a change in price of +1.53. Similarly, Cardiff Oncology Inc recorded 1,670,203 in trading volume during the last 100 days, posting a change of +55.84%.
CRDF’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CRDF stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
CRDF Stock Stochastic Average
As of today, the raw stochastic average of Cardiff Oncology Inc over the last 50 days is at 58.29%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 47.45%. Further, the company’s Stochastic %K and %D values for the last 20 days were 19.72% and 21.04%, respectively.
